|
|
|||
| |||||||||||||||||||||||||||||||||||||
About 40 years ago, when I started seeing patients in my specialty of infectious diseases, systemic fungal infections were relatively uncommon. The literature consisted mostly of case reports and uncontrolled descriptive studies, and little time was given to discussing clinical mycology at national meetings. Times have changed. Clinical mycology could almost warrant a subspecialty designation because of the number of patients who are infected, the expansion of literature that deals with the basic mechanism of pathogenesis and virulence of fungal infections, and the number of controlled clinical studies on the topic. Forty years ago, the only drug that was available
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |